

CURRICULUM VITAE AND BIBLIOGRAPHY

Name: Jeffrey I. Cohen

Education:

1976 - B.A., University of Pennsylvania
1981 - M.D., Johns Hopkins University

Postdoctoral Training:

1981-1982 Intern in Medicine, Duke University Medical Center
1982-1984 Resident, Duke University Medical Center
1984-1987 Medical Staff Fellow, Hepatitis Virus Section, Laboratory of Infectious Diseases, NIH, Bethesda, MD
1987-1988 Clinical Fellow in Medicine, Division of Infectious Diseases, Beth Israel and Brigham & Women's Hospital, Boston, MA
1988-1989 Research Fellow in Medicine and in Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA

Employment:

1989-1990 Instructor in Medicine, Harvard Medical School, Boston, MA
1990-1994 Senior Staff Fellow, Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, MD
1991- Attending Physician, Infectious Disease Consultation Service
1994-1997 Head, Molecular Virology Unit; Senior Investigator, Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, MD
1997-2003 Head, Medical Virology Section; Senior Investigator, Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, MD
2004- Head, Medical Virology Section; Senior Investigator, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, MD
2010- Chief, Laboratory of Infectious Disease, National Institutes of Health, Bethesda, MD

Licensure and Certification:

1984 Diplomate American Board of Internal Medicine
1988 Diplomate Subspecialty of Infectious Disease
1990 Maryland State Medical License

Awards and Honors:

1990 Maxwell Finland Young Investigator Award in Infectious Diseases, Harvard Medical School
1996 National Institutes of Health Merit Award
2000 NIH Director's Award
2004 Varicella-Zoster Virus Research Foundation Scientific Achievement Award

2006 NIH Distinguished Clinical Teacher Award Finalist

Editorial Boards and Review:

2002- Faculty of 1000, contributing faculty member
2003- Editorial Board, Virology
2005-2010 Editorial Board, Antiviral Therapy
2005- Editorial Board, Journal of Virology
2006- Editorial Board, Journal of Infectious Diseases
2008- Editorial Board, Virus Genes
2011- Associate Editor, Fields Virology

Societies:

1995- American Society of Clinical Investigation, member
1996- Infectious Diseases Society of America, fellow
2004-5 Greater Washington Infectious Disease Society, secretary/treasurer
2004- American Association of Physicians, member
2005-6 Greater Washington Infectious Disease Society, vice president
2006-7 Greater Washington Infectious Disease Society, president

Major Research Interests:

Virus vaccines
Virus pathogenesis
Molecular genetics of herpesviruses

Committees:

October 1993 to September 1994: Vice Chairman, NIAID Institutional Review Board
October 1994 to September 1995: Chairman, NIAID Institutional Review Board
February 1996 to April 1999: Member, NIH Institutional Biosafety Committee
May 1999 to March 2002: Chairman, NIH Institutional Biosafety Committee
January 1996 to December 1998: Cochairman, NIH Virology Interest Group
September 2005 to 2008: Shingles Working Group of the CDC Advisory Committee on Immunization Practices
September 2005 to present: PHS Technology Transfer Policy Board
September 2006 to 2010: Chairman, Great Teachers Lecture Series at NIH Clinical Center Grand Rounds
September 2010 to present: Zoster Working Group of the CDC Advisory Committee on Immunization Practices

Selected Publications from 200:

Cohen JI, Seidel KE. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc. Natl. Acad. Sci. USA 1993; 90:7376-7380.

Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen JI. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol. 1995;69:8109-8113.

Xia D, Srinivas S, Sato H, Pesnicak L, Straus SE, Cohen JI. Varicella-zoster virus ORF21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol 2003, 77: 1211-1218.

Visalli RJ, Fairhurst J, Srinivas S, Hu W, Feld B, DiGrandi M, Curran K, Ross A, Bloom JD, van Zeijl M, Jones TR, O'Connell, Cohen JI. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol 2003;77: 2349-2358.

Cohen JI, Krogmann T, Bontems S, Sadzot C, Pesnicak L. Regions of the varicella-zoster virus ORF63 latency-associated protein important for efficient replication in vitro are also critical for efficient establishment of latency. J. Virol. 2005; 79 5069-5077

Li Q, Ali, MA, Cohen JI. Insulin degrading enzyme is a cellular receptor for varicella-zoster virus infection and for cell-to-cell spread of virus. Cell 2006, 127:305-316.

Cohen JI, Straus SE, Arvin AM. Varicella-zoster virus: Replication, pathogenesis, and management. In: Knipe DM, Howley PM, et al. Fields Virology. Philadelphia, Lipincott-Williams & Wilkins, 2007, pages 2773-2818.

Cohen JI. Strategies for zoster vaccination in immunocompromised patients. J Infect Dis, 2008; 197 (S2):S237-S241.

Li Q, Krogmann K, Ali MA, Tang W-J, Cohen JI. The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin degrading enzyme, a VZV receptor. J Virol 2007; 81:8525-8532.

Ambagala AP, Bosma T, Ali MA, Poustovoitov M, Gershon MD, Adams PD, Cohen JI. Varicella-Zoster Virus Immediate-Early 63 Protein Interacts with Human Anti-Silencing Function 1 Protein and Alters its Ability to Bind Histones H3.1 and H3.3. J Virology 2008, 83:200-9.

Li Q, Ali MA, Wang K, Sayre D, Hamel FG, Fischer ER, Bennett RG, Cohen JI. Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability. PLOS ONE, 2010, 25;5(6):e11327.